Shionogi reports positive results from RSV antiviral human challenge trial conducted by hVIVO Human challenge trials provide valuable insights to accelerate candidate development
hVIVO PLC (AIM:HVO) RSV contract signed with Inhalon Biopharma
RSV human challenge trial contract signed with new client, Inhalon Biopharma
hVIVO PLC (AIM:HVO) Trading update, Record performance in 2024
hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides
hVIVO PLC (AIM:HVO) Acquisition: two Clinical Research Units from CRS
Acquisition of two Clinical Research Units from CRS for €10.0m
hVIVO PLC (AIM:HVO) LOI signed for Phase 3 Whooping Cough trial
LOI signed with ILiAD Biotechnologies for Pivotal Phase 3 Human Challenge Trial to Assess BPZE1, ILiAD’s Whooping Cough Vaccine Candidate
hVIVO PLC (AIM:HVO) £3.2m hLAB project
Largest standalone lab contract signed to date
hVIVO PLC (AIM:HVO) hMPV challenge model update
Highlights
hVIVO – A Retail Investor’s Opportunity in Healthcare Innovation
If you’re scouting for a standout healthcare stock to watch in 2025, hVIVO is worth your attention. As a global leader in human challenge trials, this innovative contract research organization (CRO) is
hVIVO PLC (AIM:HVO) COVID-19 study published in Nature Communications
COVID-19 characterisation study published in peer-reviewed Nature Communications
hVIVO PLC (AIM:HVO) £11.5m RSV contract and notice of trading update
£11.5 million RSV contract signed with existing top-tier global pharmaceutical client
hVIVO PLC (AIM:HVO) Presentation at Jefferies London Healthcare Conference
hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Yamin ‘Mo’
Executive Insights : Interview with Cathal Friel, Chair & Co-Founder of hVIVO PLC
Interview with Cathal Friel, Chair & Co-Founder of hVIVO PLC, by Brian Egan, Partner at KPMG Ireland Discover how to scale a company from startup to billion-euro enterprise with Cathal